VILERM TABLET 800 mg

País: Singapur

Idioma: anglès

Font: HSA (Health Sciences Authority)

ingredients actius:

ACYCLOVIR

Disponible des:

JOYSON PTE. LTD.

Codi ATC:

J05AB01

Dosis:

800 mg

formulario farmacéutico:

TABLET

Composición:

ACYCLOVIR 800 mg

Vía de administración:

ORAL

tipo de receta:

Prescription Only

Fabricat per:

SIAM BHEASACH CO LTD

Estat d'Autorització:

ACTIVE

Data d'autorització:

1997-04-16

Fitxa tècnica

VILERM
® (200 MG TABLET)
Each tablet contains Acyclovir 200 mg
VILERM
® (400 MG TABLET)
Each tablet contains Acyclovir 400 mg
VILERM
® (800 MG TABLET)
Each tablet contains Acyclovir 800 mg
(INN name : Aciclovir)
PRODUCT DESCRIPTION:-
VILERM
® (200 MG TABLET)
Light blue, hexagonal and flat tablet with logo “
” one side and
“VILERM 200” on the other
VILERM
® (400 MG TABLET)
Yellow, hexagonal and flat tablet with logo “
” one side and
“VILERM 400” on the other
VILERM
® (800 MG TABLET)
Light blue, oblong and biconvex tablet with “VILERM” one side and
“800”
on the other
PROPERTIES :-
PHARMACODYNAMICS :-
Mechanism of Action
Acyclovir is a synthetic purine nucleoside analogue with inhibitory
activity against
human herpes viruses, including Herpes simplex virus (HSV) types 1 and
2,
Varicella zoster virus (VZV), Epstein Barr virus (EBV) and
Cytomegalovirus (CMV).
The enzyme thymidine kinase (TK) of normal, non-infected cells does
not use
acyclovir effectively as a substrate, hence toxicity to mammalian host
cells is low;
however, TK encoded by HSV, VZV and EBV converts acyclovir to
acyclovir
monophosphate, a nucleoside analogue, which is further converted to
the diphosphate and finally to the triphosphate by cellular enzymes.
Acyclovir triphosphate interferes with the viral DNA polymerase and
inhibits viral
DNA replication with the resultant chain termination following its
incorporation
into the viral DNA.
Pharmacodynamic Effects
Prolonged or repeated course of acyclovir in severely
immunocompromised
individuals may results in the selection of virus strains with reduced
sensitivity,
which may not respond to be continued acyclovir treatment. All
patients
should be cautioned to ensure they avoid the potential of virus
transmission,
particularly when active lesions are present.
PHARMACOKINETICS :-
Acyclovir is only partially absorbed from the gut. Mean steady state
peak plasma
concentrations (C
ss
max) following doses of 200 mg administered four-hourly
were 3.1
μ
Mol (0.7
μ
g/mL) and equivalen